Intertrochanteric FracturesNCT07892859
Liposomal Bupivacaine Fascia Iliaca Block for Perioperative Sleep Quality in Elderly Patients With Intertrochanteric Fracture
A study testing Liposomal Bupivicaine and Saline Solution (NaCl 0,9%) in people with Intertrochanteric Fractures and Hip Fractures, run by Li Xiaoyuan at 1 site in China.
Trial summary
Older adults with hip fracture often experience severe pain before and after surgery. This pain can cause anxiety and poor sleep, and may increase the risk of postoperative delirium (sudden confusion after surgery). Read more about this study
- Who is it for?
- Ages 65 to 80 years
- Conditions the study is for
- Intertrochanteric Fractures, Hip Fractures, Sleep Disturbance
- What is being tested?
- Liposomal Bupivicaine and Saline Solution (NaCl 0,9%)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2026to 10 Sep 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 to 80 years
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- 1. Written informed consent signed by the patient or authorized legal representative 2. Unilateral intertrochanteric femoral fracture scheduled for closed reduction and PFNA internal fixation under intrathecal (neuraxial) anesthesia 3. Age 65-80 years, either sex 4. American Society of Anesthesiologists (ASA) physical status II-III 5. Body mass index 18-30 kg/m2
Who cannot join
- 1. Known allergy to lidocaine, bupivacaine, or liposomal bupivacaine 2. Trauma or infection at the puncture site, or coagulation disorder 3. Severe cardiac, pulmonary, hepatic, or renal insufficiency, or neurological disease 4. Severe cardiac arrhythmia 5. Long-term use or abuse of analgesic medications 6. Severe preoperative cognitive impairment precluding study assessments 7. History of psychiatric disorders (e.g., depression, anxiety disorder) 8. Pre-existing sleep disorder
Trial locations and contacts
1 site in 1 country.
China1 site
Hebei Province Cangzhou Integrated Chinese and Western Medicine Hospital
Cangzhou, Hebei, 061000
About this study
Official title: Effect of Preemptive Analgesia With Liposomal Bupivacaine Fascia Iliaca Compartment Block on Perioperative Sleep Quality, Anxiety, and Postoperative Delirium in Elderly Patients Undergoing Intertrochanteric Fracture Surgery: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Single-Center Trial
Older adults with hip fracture often experience severe pain before and after surgery. This pain can cause anxiety and poor sleep, and may increase the risk of postoperative delirium (sudden confusion after surgery). A fascia iliaca compartment block (FICB) is an injection of numbing medicine near the hip nerves that relieves pain, but standard numbing medicines only last about 8 to 12 hours. Liposomal bupivacaine is a long-acting form of a numbing medicine that may relieve pain for up to 72 hours after a single injection.
This study tests whether giving an ultrasound-guided FICB with liposomal bupivacaine immediately after hospital admission (before surgery) improves sleep quality, reduces anxiety and pain, lowers the need for opioid pain medicines, and reduces postoperative delirium in patients aged 65 to 80 years undergoing surgery for intertrochanteric hip fracture, compared with a placebo (saline) injection. All participants in both groups receive the same standard pain treatment, including scheduled intravenous dexketoprofen and patient-controlled analgesia after surgery.
Read the detailed description
This is a prospective, randomized, placebo-controlled, double-blind, single-center trial. Eighty patients aged 65-80 years (ASA physical status II-III) scheduled for closed reduction and proximal femoral nail antirotation (PFNA) fixation of a unilateral intertrochanteric femoral fracture under intrathecal anesthesia are randomized 1:1 to two groups.
Immediately after enrollment on admission, the intervention group (Group Z) receives an ultrasound-guided suprainguinal fascia iliaca compartment block (FICB) with liposomal bupivacaine 133 mg diluted to 40 mL with normal saline; the control group (Group D) receives 40 mL of normal saline by the identical technique. The block is performed by a single experienced anesthesiologist using a high-frequency linear probe and an in-plane technique, with the "hill sign" view (subcutaneous tissue, abdominal wall muscles, fascia iliaca, iliacus muscle, and ilium) confirming correct injection between the fascia iliaca and the iliacus muscle. Sensory blockade is assessed 20 minutes after injection by a blinded anesthesiologist using pinprick in the femoral, obturator, and lateral femoral cutaneous nerve territories; results are sealed and not used for clinical decisions until unblinding.
Both groups receive identical multimodal baseline analgesia (intravenous dexketoprofen trometamol 100 mg twice daily until the day of surgery), identical standardized spinal anesthesia (0.75% bupivacaine 1 mL diluted to 3 mL with cerebrospinal fluid at L3-4) with intraoperative dexmedetomidine infusion (0.3 microgram/kg/h), standardized hemodynamic management, and identical postoperative sufentanil-based patient-controlled intravenous analgesia (PCIA; sufentanil 1 microgram/kg in 150 mL, background 2 mL/h, bolus 2 mL, lockout 15 min). Rescue analgesia (intramuscular tramadol 50 mg) is given when resting VAS >= 4 despite PCIA.
Randomization is performed with an online random number generator (Research Randomizer) with allocation concealment using sealed opaque envelopes opened only by the study-drug preparation nurse, who does not participate in block performance, outcome assessment, or data analysis. Participants, the anesthesiologist performing the block, outcome assessors, and the statistician are blinded to group allocation.
The primary outcome is the Leeds Sleep Evaluation Questionnaire (LSEQ) score on the night of admission (the first night after the intervention). Secondary outcomes include LSEQ scores on the night of surgery and the second postoperative night, objective sleep parameters derived from a wrist-worn activity tracker (Fitbit Charge 6), anxiety scores, postoperative pain scores, perioperative sufentanil consumption, rescue analgesia, incidence of postoperative delirium (assessed twice daily on postoperative days 1-3 with the Confusion Assessment Method), time to first ambulation, postoperative length of stay, and adverse events.
The planned sample size of 40 per group provides 80% power (two-sided alpha = 0.05) to detect a between-group difference of approximately 34 points in the primary outcome assuming a pooled standard deviation of 52 points (based on an internal pilot study), allowing for 10% attrition.
- Conditions
- Intertrochanteric Fractures, Hip Fractures, Sleep Disturbance, Postoperative Delirium, Anxiety
- Being tested
- Liposomal Bupivicaine, Saline Solution (NaCl 0,9%)
- Keywords
- liposomal bupivacaine, fascia iliaca compartment block, preemptive analgesia, sleep quality, elderly, hip fracture, postoperative delirium
- Medical subject headings
- Hip Fractures, Parasomnias, Emergence Delirium, Anxiety Disorders, Sleep Initiation and Maintenance Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Liposomal BupivicaineDrug
1.Arm 1 - Experimental: Liposomal bupivacaine group (Group Z)
- Intervention (Drug): Liposomal Bupivacaine
- Description: Single ultrasound-guided suprainguinal FICB injection of liposomal bupivacaine 133 mg/10 mL diluted to 40 mL with 0.9% saline, injected between the fascia iliaca and iliacus muscle.
Saline Solution (NaCl 0,9%)Drug
2.Arm 2 - Placebo Comparator: Saline group (Group D)
- Intervention (Drug): Normal saline
- Description: Single ultrasound-guided suprainguinal FICB injection of 40 mL 0.9% sodium chloride solution (placebo).
| Study group | Role | What they receive |
|---|---|---|
| Experimental: Liposomal bupivacaine group (Group Z) | Experimental | Ultrasound-guided suprainguinal fascia iliaca compartment block with liposomal bupivacaine 133 mg diluted to 40 mL with normal saline, performed immediately after admission/enrollment. Receives: Drug: Liposomal Bupivicaine |
| Placebo Comparator: Saline group (Group D) | Placebo comparator | Ultrasound-guided suprainguinal fascia iliaca compartment block with 40 mL of 0.9% normal saline, performed immediately after admission/enrollment by the identical technique. Receives: Drug: Saline Solution (NaCl 0,9%) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Leeds Sleep Evaluation Questionnaire (LSEQ) score on the night of admission
Total LSEQ score (10 items, each scored on a 100-mm visual analogue line; total range 0-1000; higher scores indicate better sleep) for the night of admission, i.e., the first night after the study intervention, assessed the following morning by a blinded assessor.
Measured: Night of admission (within approximately 24 hours after the intervention)
Secondary outcomes (9)
LSEQ score on the night of surgery
Measured: Night of the day of surgery
LSEQ score on the second postoperative night
Measured: Postoperative day 2 (night)
Total sleep time (wristband actigraphy)
Measured: Objective total sleep time (hours) recorded by a wrist-worn activity tracker (Fitbit Charge 6). Time Frame: Night of admission, night of surgery, and second postoperative night
Deep sleep time (wristband actigraphy)
Measured: Night of admission, night of surgery, and second postoperative night
Number of nocturnal awakenings (wristband actigraphy)
Measured: Night of admission, night of surgery, and second postoperative night
Anxiety score (VAS-A)
Measured: Night of admission, night of surgery, and second postoperative night
Resting pain score (VAS)
Measured: 6, 24, and 48 hours after surgery
Cumulative sufentanil consumption
Measured: 0-48 hours after surgery
Number of effective PCIA demands
Measured: 0-48 hours after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Oct 2026
- Study start1 Jan 2026
- Primary completion1 Sep 2026
- Study completion10 Sep 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intertrochanteric FracturesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Li Xiaoyuan
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Li Xiaoyuan, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07892859
- Sponsor's protocol ID
- CangzhouH CZX2025-KY086-02
- Status last verified
- Oct 2026
- First submitted
- 18 Oct 2026
- Last updated
- 23 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 23 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Preemptive Analgesia With Liposomal Bupivacaine Fascia Iliaca Compartment Block on Perioperative Sleep Quality, Anxiety, and Postoperative Delirium in Elderly Patients Undergoing Intertrochanteric Fracture Surgery: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Single-Center Trial
- ClinicalTrials.gov ID
- NCT07892859
- Acronym / sponsor ID
- CangzhouH CZX2025-KY086-02
- Conditions
- Intertrochanteric Fractures, Hip Fractures, Sleep Disturbance, Postoperative Delirium, Anxiety
- Keywords
- liposomal bupivacaine, fascia iliaca compartment block, preemptive analgesia, sleep quality, elderly, hip fracture, postoperative delirium
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Li XiaoyuanUniversity, hospital or other
- Study start
- 1 Jan 2026 (actual)
- Primary completion
- 1 Sep 2026 (actual)
- Study completion
- 10 Sep 2026 (actual)
- First posted
- 23 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Older adults with hip fracture often experience severe pain before and after surgery. This pain can cause anxiety and poor sleep, and may increase the risk of postoperative delirium (sudden confusion after surgery). A fascia iliaca compartment block (FICB) is an injection of numbing medicine near the hip nerves that relieves pain, but standard numbing medicines only last about 8 to 12 hours. Liposomal bupivacaine is a long-acting form of a numbing medicine that may relieve pain for up to 72 hours after a single injection.
This study tests whether giving an ultrasound-guided FICB with liposomal bupivacaine immediately after hospital admission (before surgery) improves sleep quality, reduces anxiety and pain, lowers the need for opioid pain medicines, and reduces postoperative delirium in patients aged 65 to 80 years undergoing surgery for intertrochanteric hip fracture, compared with a placebo (saline) injection. All participants in both groups receive the same standard pain treatment, including scheduled intravenous dexketoprofen and patient-controlled analgesia after surgery.
Detailed description
This is a prospective, randomized, placebo-controlled, double-blind, single-center trial. Eighty patients aged 65-80 years (ASA physical status II-III) scheduled for closed reduction and proximal femoral nail antirotation (PFNA) fixation of a unilateral intertrochanteric femoral fracture under intrathecal anesthesia are randomized 1:1 to two groups.
Immediately after enrollment on admission, the intervention group (Group Z) receives an ultrasound-guided suprainguinal fascia iliaca compartment block (FICB) with liposomal bupivacaine 133 mg diluted to 40 mL with normal saline; the control group (Group D) receives 40 mL of normal saline by the identical technique. The block is performed by a single experienced anesthesiologist using a high-frequency linear probe and an in-plane technique, with the "hill sign" view (subcutaneous tissue, abdominal wall muscles, fascia iliaca, iliacus muscle, and ilium) confirming correct injection between the fascia iliaca and the iliacus muscle. Sensory blockade is assessed 20 minutes after injection by a blinded anesthesiologist using pinprick in the femoral, obturator, and lateral femoral cutaneous nerve territories; results are sealed and not used for clinical decisions until unblinding.
Both groups receive identical multimodal baseline analgesia (intravenous dexketoprofen trometamol 100 mg twice daily until the day of surgery), identical standardized spinal anesthesia (0.75% bupivacaine 1 mL diluted to 3 mL with cerebrospinal fluid at L3-4) with intraoperative dexmedetomidine infusion (0.3 microgram/kg/h), standardized hemodynamic management, and identical postoperative sufentanil-based patient-controlled intravenous analgesia (PCIA; sufentanil 1 microgram/kg in 150 mL, background 2 mL/h, bolus 2 mL, lockout 15 min). Rescue analgesia (intramuscular tramadol 50 mg) is given when resting VAS >= 4 despite PCIA.
Randomization is performed with an online random number generator (Research Randomizer) with allocation concealment using sealed opaque envelopes opened only by the study-drug preparation nurse, who does not participate in block performance, outcome assessment, or data analysis. Participants, the anesthesiologist performing the block, outcome assessors, and the statistician are blinded to group allocation.
The primary outcome is the Leeds Sleep Evaluation Questionnaire (LSEQ) score on the night of admission (the first night after the intervention). Secondary outcomes include LSEQ scores on the night of surgery and the second postoperative night, objective sleep parameters derived from a wrist-worn activity tracker (Fitbit Charge 6), anxiety scores, postoperative pain scores, perioperative sufentanil consumption, rescue analgesia, incidence of postoperative delirium (assessed twice daily on postoperative days 1-3 with the Confusion Assessment Method), time to first ambulation, postoperative length of stay, and adverse events.
The planned sample size of 40 per group provides 80% power (two-sided alpha = 0.05) to detect a between-group difference of approximately 34 points in the primary outcome assuming a pooled standard deviation of 52 points (based on an internal pilot study), allowing for 10% attrition.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental: Liposomal bupivacaine group (Group Z) | Experimental | Drug: Liposomal BupivicaineUltrasound-guided suprainguinal fascia iliaca compartment block with liposomal bupivacaine 133 mg diluted to 40 mL with normal saline, performed immediately after admission/enrollment. |
| Placebo Comparator: Saline group (Group D) | Placebo comparator | Drug: Saline Solution (NaCl 0,9%)Ultrasound-guided suprainguinal fascia iliaca compartment block with 40 mL of 0.9% normal saline, performed immediately after admission/enrollment by the identical technique. |
Who may qualify
- Ages
- 65 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (1 listed)
- 1. Written informed consent signed by the patient or authorized legal representative 2. Unilateral intertrochanteric femoral fracture scheduled for closed reduction and PFNA internal fixation under intrathecal (neuraxial) anesthesia 3. Age 65-80 years, either sex 4. American Society of Anesthesiologists (ASA) physical status II-III 5. Body mass index 18-30 kg/m2
Key exclusion criteria (1 listed)
- 1. Known allergy to lidocaine, bupivacaine, or liposomal bupivacaine 2. Trauma or infection at the puncture site, or coagulation disorder 3. Severe cardiac, pulmonary, hepatic, or renal insufficiency, or neurological disease 4. Severe cardiac arrhythmia 5. Long-term use or abuse of analgesic medications 6. Severe preoperative cognitive impairment precluding study assessments 7. History of psychiatric disorders (e.g., depression, anxiety disorder) 8. Pre-existing sleep disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Liposomal Bupivicaine1.Arm 1 - Experimental: Liposomal bupivacaine group (Group Z) * Intervention (Drug): Liposomal Bupivacaine * Description: Single ultrasound-guided suprainguinal FICB injection of liposomal bupivacaine 133 mg/10 mL diluted to 40 mL with 0.9% saline, injected between the fascia iliaca and iliacus muscle. | Drug | Experimental: Liposomal bupivacaine group (Group Z) |
| Saline Solution (NaCl 0,9%)2.Arm 2 - Placebo Comparator: Saline group (Group D) * Intervention (Drug): Normal saline * Description: Single ultrasound-guided suprainguinal FICB injection of 40 mL 0.9% sodium chloride solution (placebo). | Drug | Placebo Comparator: Saline group (Group D) |
Primary outcome
Leeds Sleep Evaluation Questionnaire (LSEQ) score on the night of admission
Time frame: Night of admission (within approximately 24 hours after the intervention)
Total LSEQ score (10 items, each scored on a 100-mm visual analogue line; total range 0-1000; higher scores indicate better sleep) for the night of admission, i.e., the first night after the study intervention, assessed the following morning by a blinded assessor.
9 secondary outcomes
LSEQ score on the night of surgery
Time frame: Night of the day of surgery
LSEQ score on the second postoperative night
Time frame: Postoperative day 2 (night)
Total sleep time (wristband actigraphy)
Time frame: Objective total sleep time (hours) recorded by a wrist-worn activity tracker (Fitbit Charge 6). Time Frame: Night of admission, night of surgery, and second postoperative night
Deep sleep time (wristband actigraphy)
Time frame: Night of admission, night of surgery, and second postoperative night
Number of nocturnal awakenings (wristband actigraphy)
Time frame: Night of admission, night of surgery, and second postoperative night
Anxiety score (VAS-A)
Time frame: Night of admission, night of surgery, and second postoperative night
Resting pain score (VAS)
Time frame: 6, 24, and 48 hours after surgery
Cumulative sufentanil consumption
Time frame: 0-48 hours after surgery
Number of effective PCIA demands
Time frame: 0-48 hours after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Intertrochanteric Fractures
Recruiting
Monitored Anesthesia Care and Soft Tissue Infiltration With Local Anesthesia Feasibility Trial
Hip Fracture Surgeries, Intertrochanteric Fracture
RecruitingObservational study
Cohort Study on the Prognosis and Influencing Factors in Elderly Patients With Hip Fractures in Multicenter of China
Hip Fractures (i.e. Femoral Neck or Intertrochanteric Hip Fractures)
Recruiting
Influence of Cemented Cephalic Augmentation on the Outcome of Intramedullary Nailing in Pertrochanteric Hip Fractures
Hip Fracture of Intertrochanteric Type
Not yet recruiting
FICB for Hip Fracture Pain in Elderly
Hip Fractures (i.e. Femoral Neck or Intertrochanteric Hip Fractures), Postoperative Pain
Recruiting
Robot-Assisted Closed Reduction and Internal Fixation for Intertrochanteric Femoral Fractures
Intertrochanteric Fractures, Intertrochanteric Fractures of the Hip
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Liposomal Bupivicaine and Saline Solution (NaCl 0,9%) in people with Intertrochanteric Fractures and Hip Fractures, run by Li Xiaoyuan at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Leeds Sleep Evaluation Questionnaire (LSEQ) score on the night of admission (time frame: Night of admission (within approximately 24 hours after the intervention)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2026.